Strategy choice of hormonal contraception in women with androgen dependent dermopathy and associated diseases


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To make a systematic review of the data available in the literature regarding the possibilities of hormonal contraception in women with androgen-dependent dermopathies. Material and methods. For analysis, foreign and Russian publications over the past 15 years were sought in the international citation system Pubmed. Results. The types of androgen-dependent dermopathies, their origin, and the mechanism of development are described; the endocrine and metabolic factors underlying the clinical symptoms of skin damage are discussed. The paper underlines the importance of diagnosis of the diseases, the symptoms of which are androgen-dependent dermopathies, and the need for symptomatic treatment of skin disorders due to their significant impact on the state of mind in women. Conclusion. The results of clinical trials that have shown the efficiency of using hormonal contraceptives to treat androgen-dependent dermopathies are analyzed. An algorithm for the individual choice of a drug in the context of the health status and wishes of a female patient is presented.

Full Text

Restricted Access

About the authors

Irina V. Kuznetsova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

MD, PhD, Chief Researcher for Women’s Health Research Center, Research Department

Parvin A. Nabiyeva

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

a graduate student of the Department of Endocrinology

References

  1. Schaefer I., Rustenbach S.J., Zimmer L., Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology. 2008; 217(2): 169-72.
  2. Clark C.M., Rudolph J., Gerber D.A., Glick S., Shalita A.R., Lowenstein E.J. Dermatologic manifestation of hyperandrogenism: a retrospective chart review. Skinmed. 2014; 12(2): 84-8.
  3. Gollnick H.P., Zouboulis C.C. Not all acne is acne vulgaris. Dtsch. Arztebl. Int. 2014; 111(17): 301-12.
  4. Nast A., Dréno B., Bettoli V., Degitz K., Erdmann R., Finlay A.Y. et al. European evidence-based (S3) guidelines for the treatment of acne. J. Eur. Acad. Dermatol. Venereol. 2012; 26(Suppl.1): 1-29.
  5. Chen W., Obermayer-Pietsch B., Hong J.B., Melnik B.C., Yamasaki O., Dessinioti C. et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J. Eur. Acad. Dermatol. Venereol. 2011; 25(6): 637-46.
  6. Schmitt J.V., Masuda P.Y., Miot H.A. Acne in women: clinical patterns in different age-groups An. Bras. Dermatol. 2009; 84(4): 349-54.
  7. Dréno B., Layton A., Zouboulis C.C., Lopez-Estebaranz J.L., Zalewska-Janowska A., Bagatin E. et al. Adult female acne: a new paradigm. J. Eur. Acad. Dermatol. Venereol. 2013; 27(9): 1063-70.
  8. Collier C.N., Harper J.C., Cafardi J.A. The prevalence of acne in adults 20 years and older. J. Am. Acad. Dermatol. 2008; 58(1): 56-9.
  9. Ghodsi S.Z., Orawa H., Zouboulis C.C. Prevalence, severity and severity risk factors of acne in high school pupils: A community-based study. J. Invest. Dermatol. 2009; 129: 2136-41.
  10. Yaykasli K.O., Turan H., Kaya E., Hatipoglu O.F. Polymorphisms in the promoters of MMP-2 and TIMP-2 genes in patients with acne vulgaris. Int. J. Clin. Exp. Med. 2013; 25; 6(10): 967-72.
  11. Bhate K., Williams H.C. Epidemiology of acne vulgaris. Br. J. Dermatol. 2013; 168: 474-85.
  12. Tanghetti E.A. The role of inflammation in the pathology of acne. J. Clin. Aestet. Dermatol. 2013; 6(9): 27-35.
  13. Emiroglu N., Cengiz F.P., Kemeriz F. Insulin resistance in severe acne vulgaris. Postepy Dermatol. Alergol. 2015; 32(4): 281-5.
  14. Gilliver S.C., Ruckshanthi J.P., Hardman M.J., Zeef L.A., Ashcroft G.S. 5alpha-dihydrotestosterone (DHT) retards wound closure by inhibiting re-epithelialization. J. Pathol. 2009; 217(1): 73-82.
  15. Chuang K.H., Altuwaijri S., Li G., Lai JJ., Chu C.Y., Lai K.P. et al. Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor. J. Exp. Med. 2009; 206(5): 1181-99.
  16. Lai J.J., Lai K.P., Chuang K.H., Chang P., Yu I.C., Lin WJ., Chang C. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J. Clin. Invest. 2009; 119(12): 3739-51.
  17. Косыгина А.В., Васюкова О.В. Новое в патогенезе ожирения: адипокины -гормоны жировой ткани. Проблемы эндокринологии. 2009; 55(1): 44-50.
  18. Harrison S., Bergfeld W. Diffuse hair loss: its triggers and management. Cleve. Clin. J. Med. 2009; 76(6): 361-7.
  19. Hillmer A.M., Brockschmidt F.F., Hanneken S, Eigelshoven S., Steffens M., Flaquer A. et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat. Genet. 2008; 40(11): 1279-81.
  20. Hillmer A.M., Flaquer A., Hanneken S., Eigelshoven S., Kortüm A.K., Brockschmidt F.F. et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am. J. Hum. Genet. 2008; 82(3): 737-43.
  21. Garza L.A., Liu Y., Yang Z., Alagesan B., Lawson J.A., Norberg S.M. et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci. Transl. Med. 2012; 4(126): 126-34.
  22. Martin K.A., Chang R.J., Ehrmann D.A., Ibanez L., Lobo R.A., Rosenfield R.L. et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J. Clin Endocrinol. Metab. 2008; 93(4): 1105-20.
  23. Cook H., Brennan K., Azziz R. Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism? Fertil. Steril. 2011; 96(5): 1266-70.
  24. Paparodis R., Dunaif A. The Hirsute woman: challenges in evaluation and management. Endocr. Pract. 2011; 17(5): 807-18.
  25. Stener-Victorin E., Holm G., Labrie F., Nilsson L., Janson P.O., Ohlsson C. et al. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J. Clin. Endocrinol.Metab. 2010; 95(2): 810-9.
  26. Gupta M., Mahajan V.K., Mehta K.S., Chauhan P.S., Rawat R. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the ’future’ in dermatology therapeutics? Arch. Dermatol. Res. 2015; 307(9): 767-80.
  27. Nissar A.S., Heath J.A., Pall M. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2008; 93: 1939-45.
  28. Macut D., Antic I.B., Bjekic-Macut J. Cardiovascular risk factors and events in women with androgen excess. J. Endocrinol. Invest. 2015; 38(3): 295-301.
  29. Halvorsen J.A., Dalgard F., Thoresen M. Is the association between acne and mental distress influenced by diet? Results from a crosssectional population study among 3775 late adolescents in Oslo, Norway. BMC Public Health. 2009; 9: 340.
  30. Himelein M.J., Thatcher S.S. Polycystic ovary syndrome and mental health: A review. Obstet. Gynecol. Surv. 2006; 61(11): 723-32.
  31. Bazarganipour F., Ziaei S., Montazeri A., Foroozanfard F., Kazemnejad A., Faghihzadeh S. Psychological investigation in patients with polycystic ovary syndrome. Health Qual. Life Outcomes. 2013; 11: 141.
  32. Geifman N., Cohen R., Rubin E. Redefining meaningful age groups in the context of disease. Age (Dordr.) 2013; 35(6): 2357-66.
  33. Kim G.K., Del Rosso J.Q. Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. J. Clin. Aesthet. Dermatol. 2012; 5(3): 37-50.
  34. Fauser B.C., Tarlatzis B.C., Rebar R.W. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRMSponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 2012; 97(1): 28-38.
  35. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013; 98(12): 4565-92.
  36. Schindler A.E. Non-contraceptive benefits of oral hormonal contraceptives. Int. J. Endocrinol. Metab. 2013; 11(1): 41-7.
  37. Goodman N.F, Cobin R.H., Futterweit W., Glueck J.S., Legro R.S., Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - part 1. Endocr. Pract. 2015; 21(11): 1291-300.
  38. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst. Rev. 2012; (7): CD004425.
  39. Hsu C.L, Liu J.S., Lin A.C., Yang C.H., Chung W.H., Wu W.G. Minoxidil may suppress androgen receptor-related functions. Oncotarget. 2014; 5(8): 2187-97.
  40. Sitruk-Ware R., Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27(1): 13-24.
  41. Anttila L., Bachmann G., Hernadi L., Kunz M., Marr J., Klipping C. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 pg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 155(2): 180-2.
  42. Sitruk-Ware R. Metabolic effects of contraceptive steroids. Rev. Endocr. Metab. Disord. 2011; 12(2): 63-75.
  43. Кузнецова И.В., Диль В.В. Предменструальный синдром и нарушения пищевого поведения. Акушерство и гинекология. 2014; 11: 63-73.
  44. Shapiro J., ed. Hair disorders: current concepts in physiopathology. Diagnosis and management. Elsevier; 2013.
  45. Berenson A.B., Odom S.D., Breitkopf C.R., Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 pg oral contraceptive pills. Am. J. Obstet. Gynecol. 2008; 199(4): 351.e1-351.
  46. Ekbäck M., Lindberg M., Benzein E., Årestedt K. Health-related quality of life, depression and anxiety correlate to the degree of hirsutism. Dermatology. 2013; 227: 278-84.
  47. Breech L.L., Braverman P.K. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int. J. Womens Health. 2009; 1: 85-95.
  48. Hall K.S., Trussed J., Schwarz E.B. Progestin-only contraceptive pill use among women in the United States. Contraception. 2012; 86(6): 653-8.
  49. Pena M.Á., Sanz E., Francisco S., Alonso A., Abajo Z., Felipe I. et al. Randomized, crossover and single-dose bioquivalence study of two oral desogestrel formulations (film-coated tablets of 75 pg) in healthy female volunteers. Sci. Pharm. 2012; 80(2): 419-31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies